Michael Makris on Immediate Suspension of Use of Plasma Derived FIX Concentrates in Punjab
Michael Makris, Emeritus Professor of Haemostasis and Thrombosis at the University of Sheffield, Editor-in-Chief of RPTH Journal, shared on LinkedIn:
”This is worrying.
The Tribune newspaper in India is reporting that authorities have asked for the immediate suspension of use (and quarantining) of six batches of plasma derived factor IX concentrate for use in haemophilia B.
The products are made by a company called ICHOR Biologics, a company I have not heard of before.
The article is missing two critical pieces of information:
a) What is the adverse event that led to the suspension of this product
b) How many patients are affected. Only the total number of patients in the region are given.
I really hope this is not new transmission of a viral infection in persons with haemophilia.
The story may be a local one in Punjab in India, but the international world of haemophilia will be following this story.”
Read The Tribune article here.
Stay updated on the emerging with Hemostasis Today.
-
Nov 19, 2025, 18:03Andres Ricaurte Fajardo on a Strongyloides Stercoralis Hyperinfection with Thrombosis
-
Nov 19, 2025, 17:50Marilena Vrana Reflects on PPTA Europe’s Visits with Members and Stakeholders in 2025
-
Nov 19, 2025, 17:32Michael Makris Shares Insights from Global Forum Meeting of the WFH Meeting in Montreal
-
Nov 19, 2025, 17:14Yazan Abou Ismail Takes The Legacy Award from Qatar Foundation
-
Nov 19, 2025, 17:02Wolfgang Miesbach Shares Real-World Evidence on Eptacog Beta from Spain
-
Nov 19, 2025, 16:34Ishita Singh Reflects on Haematocon 2025: A Reminder of Her Commitment to The Journey
-
Nov 19, 2025, 16:23Mehdi Kashani: I’m Really Excited to Share Schistosite.com
-
Nov 19, 2025, 16:09A ”Meow-cyte” from Melaku Abay Muluneh or Why Microscopy Never Gets Old!
-
Nov 19, 2025, 15:56Cuilan Li on her Contribution to a Cutting-Edge Project in Polycythemia Vera